On August 5, 2026 the U.S. Food and Drug Administration approved Orzeyful (oveporexton) tablets for the treatment of narcolepsy type 1 in adults. This approval designates Orzeyful as the first medicine to treat narcolepsy type 1 as a complete disorder and the first to act directly on the orexin signaling pathway. The approval was granted to Takeda Pharmaceuticals America, Inc. Orzeyful is taken orally twice daily.
Narcolepsy type 1 is a rare, lifelong neuropsychiatric sleep disorder affecting an estimated 1 in 2,000 people in the United States. The condition is caused by loss of brain cells that produce orexin, a neurotransmitter that regulates wakefulness, sleep, and muscle tone. Loss of orexin signaling impairs the brain’s ability to maintain alertness and to regulate transitions between sleep and wake states.
The disorder produces a cluster of disabling symptoms including excessive daytime sleepiness, cataplexy (sudden muscle weakness typically triggered by strong emotion), sleep paralysis, hypnagogic or hypnopompic hallucinations, and disrupted nighttime sleep. Prior to this approval, no medicine had been specifically approved to treat the full spectrum of narcolepsy type 1 symptoms or to target the orexin system itself.
Orzeyful (oveporexton) restores the missing biological signal by directly activating the brain receptor that endogenous orexin would normally stimulate. Rather than masking symptoms with stimulants or sedatives, Orzeyful targets the underlying neurochemical deficit believed to cause narcolepsy type 1.
The approved formulation is an oral tablet administered twice daily. The FDA information reports the typical clinical dose evaluated was 2 mg in the randomized trials. Details about titration schedules, dose adjustments, or administration relative to meals were not reported in the source.
Effectiveness and safety were evaluated in two randomized, double-blind, placebo-controlled 12-week studies that together enrolled 273 adults with narcolepsy type 1. In both trials, participants receiving Orzeyful 2 mg demonstrated improved ability to stay awake during the day compared with placebo.
Patients treated with Orzeyful also reported substantially less daytime sleepiness, a significant reduction in cataplexy episodes, and meaningful improvements across the full spectrum of narcolepsy symptoms, including sleep paralysis, hallucinations at the edge of sleep or waking, and disrupted nighttime sleep. The source did not provide numerical results, effect sizes, p values, or detailed subgroup analyses; those specific trial endpoints and quantitative outcomes were not reported in the source document.
The most commonly reported adverse events in the trials were insomnia, increased urinary frequency, urgency to urinate, and increased saliva production. The rate of treatment discontinuation due to adverse events was low. The safety and effectiveness of Orzeyful have not been established in patients younger than 18 years.
Clinicians should be aware of drug interaction risks: Orzeyful should not be used concomitantly with strong CYP3A inhibitors according to the FDA announcement. Additional prescribing details, dose-modification guidance, and monitoring recommendations beyond those safety notes were not reported in the source.
Orzeyful has been recommended for scheduling under the Controlled Substances Act; it will be lawful to market following the Drug Enforcement Administration’s scheduling decision. The FDA communication did not include the proposed schedule or timeline for the DEA decision.
Orzeyful received Breakthrough Therapy Designation and Priority Review during its development and evaluation. Breakthrough Therapy Designation facilitates intensive FDA guidance for drugs that show early evidence of substantial improvement over available therapies; Priority Review shortens the FDA’s target review time for therapies that would offer significant improvements in treating serious conditions.
The approval was granted to Takeda Pharmaceuticals America, Inc. The FDA noted that Orzeyful represents the first medicine to address narcolepsy type 1 by restoring orexin signaling and treating the disorder as a whole rather than targeting single symptoms. The source indicates that downstream regulatory steps include the DEA scheduling decision; no additional postmarketing requirements, timelines, or risk-management plans were specified in the announcement.
This approval introduces a treatment option that targets the presumed underlying biology of narcolepsy type 1 rather than primarily addressing individual symptoms. For adult patients with narcolepsy type 1, Orzeyful may reduce daytime sleepiness and cataplexy and improve associated symptoms such as sleep paralysis and hallucinations. Clinicians should counsel patients about the most frequently observed adverse events, avoid coadministration with strong CYP3A inhibitors, and note the absence of established pediatric safety and efficacy data. Specific prescribing guidance, dosing titration, and detailed efficacy metrics were not provided in the FDA press release and should be obtained from the full prescribing information when available.
The FDA press announcement provided media and consumer contact points and indicated the content was current as of August 5, 2026. For full prescribing information and labeling, clinicians should refer to the approved product labeling and Takeda’s prescribing resources once those documents are posted and after the DEA scheduling decision is issued.